2024 PARTNERS
AMRA Medical - Expertise Partner
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans.
AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical settings by offering support services via their innovative platform to help advance disease research in obesity, and beyond.
Antaros Medical - Expertise Partner
Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.
Curi Bio - Expertise Partner
"Human Data for Next Generation Medicines"
Curi Bio unlocks novel workflows and critical human data to inform R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio merges functional and analytical assessments for assessing drug safety, efficacy, and potency.
Physiogenex - Innovation Partner
Innovation Partner Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: MASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis. For >20 years, we have been evaluating the efficacy of our clients’ drugs using goldstandard experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners. Our expertise – your success.
Biomeostasis - Innovation Partner
Biomeostasis is a leading Preclinical CRO offering in vivo pharmacology services specialized in Metabolic, Liver, Gastrointestinal and Muscle-Wasting Diseases. For over 15 years, we have been assessing the efficacy and mechanisms of action of drug candidates addressing conditions such as obesity, diabetes, Atherosclerosis, MASLD/MASH, Constipation, IBD, Cachexia, Sarcopenia or DMD. We at Biomeostasis provide science-driven efficacy in vivo studies
CYTOO - Innovation Partner
CYTOO is a biotech company focused on muscle health and disease. CYTOO has pioneered MyoScreen™, an innovative in vitro screening platform that replicates the phenotypes, biomarkers and biochemical pathways affected in inherited and acquired muscle disorders. This platform, combined with our expertise in assay development and AI-driven image analysis, supports drug development at every stage of the pipeline, providing disease modeling and primary screening to functional potency assays for clinical lot release. MyoScreen has successfully advanced several drug candidates into clinical trials during >60 industrial partnerships involving small molecules, peptides, antibodies, RNA and gene therapies. Our platform addresses a broad range of disease areas, including genetic neuromuscular disorders and muscle dysfunctions resulting from metabolic disturbances.
ERG Clinical - Hosting Partner